orthospinenews.com /5 days ago

NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates

MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) — NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative…

Read source
orthospinenews.com /1 month ago

NGMEDICAL WILL PRESENT AT UPCOMING EUROSPINE AND NASS AND EXPANDS INTERNATIONAL PRESENCE

NONNWEILER, GERMANY, October 5, 2026 /EINPresswire.com/ — NGMedical will exhibit at Eurospine in Gothenburg as well as NASS in San…

Read source
seekingalpha.com /1 week ago

Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis - Slideshow

Read source
seekingalpha.com /1 month ago

NKT A/S (NRKBY) Analyst/Investor Day - Slideshow

Read source
orthotw.com /1 week ago

NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury

Breakthrough Therapy designation granted based on FDA’s review of safety and efficacy data from the chronic cohort of the Phase 1b/2a CONNECT SCI study.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.